TRexBio, Inc.

After a six-month search to find a permanent replacement for research chief John Reed, Sanofi has dipped into the venture capital sector and appointed Houman Ashrafian as its new head of R&D, effect

AstraZeneca is to work with Quell Therapeutics to develop its Treg cell therapies in two autoimmune disease areas, paying out $85m upfront in a deal which could be worth well over $2bn. The UK pharma

Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu